All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @kekes.plot on TikTok · 145s|Watch on TikTok

@kekes.plot's GLP-1 injection claims, fact-checked

Kearney’s Plot 🎥

TikTok creator

288.9K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide are injectable medications for type 2 diabetes and obesity that slow gastric emptying and increase insulin sensitivity. Semaglutide at 2.4mg weekly produced 14.9% weight loss at 68 weeks in the STEP 1 trial, while tirzepatide 15mg weekly led to 20.9% weight reduction in SURMOUNT-1.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @kekes.plot's GLP-1 injection claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@kekes.plot's GLP-1 injection claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@kekes.plot's GLP-1 injection claims, fact-checked" from Kearney's Plot 🎥. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide are injectable medications for type 2 diabetes and obesity that slow gastric emptying and increase insulin sensitivity.

The reason this review is not generic is the source wording and the canonical claim label "glp1 short answer is it takes less than 2 minutes once a week a." In this clip, the useful excerpt is: "Short answer is, it takes less than 2 minutes once a week." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Liraglutide requires daily injections, not weekly, so the timing claim doesn't apply to all GLP-1 medications
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide are injectable medications for type 2 diabetes and obesity that slow gastric emptying and increase insulin sensitivity.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide are injectable medications for type 2 diabetes and obesity that slow gastric emptying and increase insulin sensitivity. Semaglutide at 2.4mg weekly produced 14.9% weight loss at 68 weeks in the STEP 1 trial, while tirzepatide 15mg weekly led to 20.9% weight reduction in SURMOUNT-1.
  • Semaglutide and tirzepatide injections do take less than 2 minutes weekly once you're familiar with the process
  • Liraglutide requires daily injections, not weekly, so the timing claim doesn't apply to all GLP-1 medications

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Semaglutide and tirzepatide injections do take less than 2 minutes weekly once you're familiar with the process
  • Liraglutide requires daily injections, not weekly, so the timing claim doesn't apply to all GLP-1 medications
  • The STEP 1 trial found 14.9% weight loss with weekly semaglutide 2.4mg over 68 weeks
  • Dose escalation takes 16-20 weeks to reach full therapeutic doses and minimize side effects
  • 74% of patients in STEP trials experienced nausea with semaglutide 2.4mg
  • These medications require medical supervision for contraindication screening and side effect management
  • Social media advice can't replace proper medical counseling for prescription medications

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok actually claim?

Creator @kekes.plot tells viewers that GLP-1 injections take "less than 2 minutes once a week" and promises to answer "all your GLP-1 questions." The video appears to be aimed at the #glp1community, suggesting it's targeting people already using or considering medications like semaglutide or tirzepatide.

While the caption is brief, the timing claim is specific enough to fact-check. The creator positions themselves as an authority on GLP-1 medications by offering to answer questions about these prescription drugs.

Is the injection timing accurate?

The "less than 2 minutes" claim is actually generous. Most people can complete a GLP-1 injection in 30-60 seconds once they're familiar with the process. Pen injectors like those used for Ozempic and Wegovy are designed for quick subcutaneous administration.

The weekly timing applies to semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which are both dosed once weekly. However, liraglutide (Saxenda) requires daily injections. The creator doesn't specify which GLP-1 medication they're discussing, making their advice incomplete.

Clinical trials confirm the weekly dosing schedule. The STEP 1 trial (Wilding et al., NEJM, 2021) used once-weekly 2.4mg semaglutide injections, while the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) tested weekly tirzepatide doses up to 15mg.

What's missing from this advice?

The creator's promise to answer "all your GLP-1 questions" is problematic without proper medical credentials. These medications require careful dose escalation, monitoring for side effects, and contraindication screening that goes far beyond injection technique.

Semaglutide starts at 0.25mg weekly and increases to 2.4mg over 16-20 weeks to minimize gastrointestinal side effects. The STEP trials found that 74% of patients experienced nausea with the 2.4mg dose. This titration schedule isn't something you learn from TikTok.

The video also doesn't address serious considerations like contraindications in patients with medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The FDA requires black box warnings on these medications for good reason.

Should you trust TikTok for GLP-1 guidance?

While @kekes.plot gets the basic injection timing right, social media isn't the place for comprehensive medication counseling. These drugs carry significant side effects and require medical supervision.

The STEP 1 trial reported discontinuation rates of 7% due to adverse events with semaglutide versus 3.1% with placebo. Common issues include nausea (58% vs 16% placebo), diarrhea (30% vs 16%), and vomiting (24% vs 5%). You won't get proper side effect management from a 15-second TikTok.

Real medication education requires discussing individual risk factors, drug interactions, and monitoring requirements. The injection technique is the easy part.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kearney’s Plot 🎥 · TikTok creator

288.9K views on this video

Short answer is, it takes less than 2 minutes once a week. Answering all your glp-1 questions 🫶🏽 #glp #glp1community #injectionday @Freya

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide?

Semaglutide and tirzepatide injections do take less than 2 minutes weekly once you're familiar with the process

What does the video say about liraglutide requires daily injections, not weekly, so the timing claim?

Liraglutide requires daily injections, not weekly, so the timing claim doesn't apply to all GLP-1 medications

What does the video say about the step 1 trial found 14.9% weight loss with weekly?

The STEP 1 trial found 14.9% weight loss with weekly semaglutide 2.4mg over 68 weeks

Dose escalation takes 16-20 weeks to reach full therapeutic doses and minimize side effects?

Dose escalation takes 16-20 weeks to reach full therapeutic doses and minimize side effects

What does the video say about 74% of patients in step trials experienced nausea with semaglutide?

74% of patients in STEP trials experienced nausea with semaglutide 2.4mg

What does the video say about these medications require medical supervision for contraindication screening?

These medications require medical supervision for contraindication screening and side effect management

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kearney’s Plot 🎥, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.